Novo Nordisk Rallies 7% After UK Oral Wegovy Approval, DCF Values at $90
NVO•Novo Nordisk shares gained 7% in a week after U.K. regulators approved the oral version of its Wegovy weight-loss pill and executives reported robust early order volumes. A DCF model sets an intrinsic value of $90 per share against current $44 price, signaling upside despite near-term competitive and pricing pressures.
1. UK Oral Wegovy Approval Spurs Stock Rally
Shares of Novo Nordisk climbed 7% in the past week after the U.K. regulator approved the first oral formulation of Wegovy, its flagship weight-loss treatment, and management reported strong initial order volumes from European distributors.
2. DCF Valuation Suggests Upside to $90
A discounted cash flow analysis incorporating projected revenue growth, margin expansion, and a standard discount rate yields an intrinsic value of $90 per share, compared to the current price of $44, implying more than 100% upside if execution aligns with long-term forecasts.
3. Competitive and Pricing Risks Loom
Analysts highlight potential headwinds from emerging GLP-1 competitors, generic entrants, and pricing pressure in key markets that could delay margin recovery and challenge the assumptions underpinning the bullish valuation.
